Brought to you by 
Threshold gets hypoxia PET imaging agent from Siemens Healthcare
11 Feb 2022
Executive Summary
Threshold Pharmaceuticals Inc. (developing drugs that target tumor hypoxia) has acquired Siemens Healthcare’s radiolabeled hypoxia positron emission tomography (PET) tracer (18F)HF4 (flortanidazole (18F)), which it will use as a companion diagnostic for its cancer therapeutics in development.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
Deal Status
- Final
Deal Type
-
Alliance
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Threshold gets hypoxia PET imaging agent from Siemens Healthcare
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice